A novel hot-melt extrusion formulation of albendazole for increasing dissolution properties

Laura Martinez-Marcos[1,2]*, Dimitrios A. Lamprou[1,2]*, Roy T. McBurney[1,2], Gavin W. Halbert[1,2]**

[1]EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC), University of Strathclyde, Technology and Innovation Centre, 99 George Street, G1 1RD Glasgow, United Kingdom

[2]Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, G4 0RE Glasgow, United Kingdom

* Corresponding authors. E-mail address: laura.martinez-marcos@strath.ac.uk, dimitrios.lamprou@strath.ac.uk

Tel.: +441415484968

** Funded by Cancer Research UK

ABSTRACT

The main aim of the research focused on the production of hot-melt extrusion (HME) formulations with increased dissolution properties of albendazole (ABZ). Therefore, HME was applied as a continuous manufacturing technique to produce amorphous solid dispersions of the poorly water soluble drug ABZ combined with the polymer matrix polyvinylpyrrolidone PVP K12. HME formulations of ABZ – PVP K12 comprised a drug content of 1%, 5% and 10% w/w. The main analytical characterisation techniques used were Scanning Electron Microscopy (SEM), Micro-computed Tomography (μ-CT), X-Ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC) and dissolution profile

studies. The application of SEM, XRPD and DSC evidenced drug physical transformation from crystalline to amorphous state and therefore, the achievement of an amorphous solid dispersion. The introduction of a novel technique, μ-CT, to characterise the internal structure of these materials revealed key information regarding materials distribution and void content. Dissolution profile studies evidenced a high increase in drug release profile compared to pure ABZ. These promising results can lead to a great enhancement of the oral bioavailability of ABZ dosage forms. Therefore, HME is a potential continuous manufacturing technique to overcome ABZ poor solubility properties and lead to a significant increase in the therapeutic effect.

Keywords: Hot-melt extrusion; Amorphous solid dispersions; Albendazole; Continuous manufacturing; μ-CT.

1. Introduction

A major focus of current pharmaceutical industry research is directed at the need to manufacture and deliver better quality medicines in a cost efficient manner (Madan and Madan, 2012). However, the physicochemical properties of Active Pharmaceutical Ingredients (APIs) are not always ideal and properties such as poor aqueous solubility, which influences dissolution and oral bioavailability, can be detrimental during pharmaceutical development (Munos, 2009; Kawakami, 2012). APIs that exhibit low solubility properties but high permeability through biological membranes are considered Class II compounds within the Biopharmaceutics Classification System (BCS) (Lindenberg et al., 2004) and in order to overcome poor solubility properties several formulation techniques can be considered. Some of the most common approaches are the introduction of chemical transformations such as the production of salt or co-crystal forms and other process modifications for example drug

micronisation or the production of amorphous solid dispersions (Stegemann et al., 2007; Kawabata et al., 2011; Jones et al., 2014).

It has been recognised that a change in the API's molecular physical state from a crystalline ordered structure to an amorphous state dramatically enhances its solubility and dissolution properties (Zhang et al., 2004). This physical transformation of the drug can be achieved by Hot-Melt Extrusion (HME) in order to deliver an amorphous solid dispersion with increased dissolution properties, which is controlled by the polymeric carrier excipient combination employed.

HME is a widely known manufacturing process that has been used in the plastic (Michaeli et al., 1993) and food industries (Cheng and Friis, 2010) and more recently, in the pharmaceutical industry (Crowley et al., 2007). In HME, a hydrophilic polymeric carrier and a poor water soluble drug are homogeneously mixed to form a molecular solid dispersion (Repka et al., 2007). HME can be achieved using a single or twin-screw extruder, both types have been widely studied and the advantages and disadvantages regarding the material mixing achieved reviewed (Van zuilichem et al., 1999). Selection of the components must be carefully performed taking into account the melt temperature (Tm) of both the polymer and the API as well as the glass transition temperature (Tg) of the polymer. These parameters play a key role in obtaining an amorphous solid dispersion as well as being key determinants of product stability (Newman et al., 2012). Initial assessment of the solubility properties can be performed by evaluating drug-polymer miscibility properties or also by using a mathematical approach such as the *Hoy and Hoftzyer/Van Krevelen* method (Forster et al., 2001). After production, characterisation techniques such as X-Ray Powder Diffraction (XRPD) and thermal analysis by Differential Scanning Calorimetry (DSC) constitute important techniques for the assessment of drug solid state (Maniruzzaman et al., 2013). Previous HME applications have focused on the development of new drug delivery systems

such as sustained released or taste-masking formulations (Maniruzzaman et al., 2012; Gue et al., 2013; Schilling and McGinity, 2010; Verhoeven et al., 2009b). By applying modelling techniques such as Computational Fluid Dynamics (CFD), Eitzlmayr et al., (2014), demonstrated that HME processes can be fully designed and noted the importance of selecting adequate screw elements configuration as this has an impact on the screws filling degree and therefore the heat transfer mechanisms within the extruder. Moreover, processing parameters such as melt temperature can be calculated taking into account the polymer's and API's viscosity values. Finally Quality by Design (QbD) has emerged as a potent tool to investigate the working space limits of HME processes based on the desired product specifications (Thiry et al., 2015; Maughan and Rhamzan, 2012).

The main aim of this research comprised the development and characterisation of novel albendazole (ABZ) formulations manufactured by continuous HME processing to improve ABZ dissolution properties and determine the influence of different drug contents in relation to material properties such as drug content uniformity, materials homogeneity and internal porosity by the application of a novel technique such as micro computed tomography (µ-CT). ABZ is an anthelmintic drug used in the treatment of hydatid disease, among other parasitic worm infestations. Reported physicochemical properties of ABZ such as a low aqueous solubility of 0.0228 mg/mL and a melting temperature (Tm) of 208°C were crucial to determine the suitability of this drug molecule for HME processing. APIs with a high melting point are preferred to avoid any degradation product as it has been previously observed using temperature sensitive drugs. It is also widely known that the low solubility and dissolution rate of ABZ lead to erratic absorption (below 5%) from the gastrointestinal tract mainly observed through pharmacokinetic studies (Marriner et al., 1986; Jung et al., 1998). Moreover, Newman et al., (2012), classified ABZ as one of the BCS II compounds where a

solid phase transformation using a hydrophilic polymer such as PVP could become a suitable approach towards the enhancement of its oral bioavailability.

Previous work comprising solid dispersions of ABZ and PVP K12 manufactured by solvent evaporation method was carried out by Torrado et al., (1996) in order to improve ABZ dissolution rate. In our study we were able to successfully produce stable amorphous solid dispersions of ABZ by HME process with increased dissolution properties and provide novel characterisation studies by the application of μ-CT.

2. Materials and methods

2.1. Materials

Albendazole (ABZ, ≥98 %) was purchased from Sigma-Aldrich Company Ltd. (Gillingham, Dorset, United Kingdom). Pharmaceutical grade polyvinylpyrrolidone K12 (PVP K12 PF), was kindly donated by BASF (Cheshire, United Kingdom). Other reagents such as methanol (HPLC grade, ≥99.5 %), potassium chloride AR grade, sodium dihydrogen phosphate (>99.0 %) and glacial acetic acid (ACS reagent, ≥99.7 %) were obtained from Sigma-Aldrich.

2.2. Miscibility studies

Miscibility properties of ABZ and PVP K12 were theoretically assessed using the Hansen solubility parameter calculations and confirmed by hot-stage microscopy (HSM) using a Reichert-Jung polyvar optical microscope fitted with a hot-stage. Raw materials, physical mixtures (PM) at 1/99, 5/95 and 10/90 % w/w and extruded materials were studied using a heating rate of 10 °C/min.

2.3. Continuous manufacturing by Hot-Melt Extrusion (HME)

Formulations of ABZ and PVP K12 comprising 1/99, 5/95 and 10/90 (% w/w) (F1, F2 and F3, total sample weight of 50 g) were prepared (Jones et al., 2014; Kelly et al., 2015). Previous sieving of PVP K12 through a mesh of 250 μm was carried out for particle size

homogenisation purposes. Physical mixtures of ABZ – PVP K12 were manually blended for 2-5 minutes prior extrusion. All formulations were processed by HME using a Thermo Scientific® Process 11 co-rotating twin-screw extruder (40L/D) (Karlsruhe, Germany) with the following standard screw configuration: (FS 11/40) x 7 + (KE 10/90°) x 8 + (KE 10/60°) x 4(F) + (FS 11/40) x 8 + (KE 10/60°) x 6(F) + (FS 11/40) x 7 + (KE 10/90°) x 4 + (KE 10/60°) x 3(F) + (KE 10/30°) x 5(F) + (FS 11/40) x 9; (FS 11/40: feed screw with a pitch of 11 mm and length of 40 mm; KE 10/90°: kneading element with thickness of 10 mm and 90° offset angle; KE 10/60°: kneading element with thickness of 10 mm and 60° offset angle; KE 10/30°: kneading element with thickness of 10 mm and 30° offset angle; F: forward). The 11 mm screw diameter extruder was fitted with a single orifice die of 2.0 mm diameter and processing parameters are presented in Table 1. Cooling of the strands was performed at room temperature and then stored in a sealed glass container under temperature controlled conditions of 25 °C and 50 °C. Initial studies of all extruded materials were performed at zero time and stability studies performed after 1, 3 and 6 months storage under conditions indicated in the text.

2.4. Scanning Electron Microscopy (SEM)

HME formulations containing ABZ – PVP K12 were analysed by SEM for the presence of crystalline ABZ. Gold-coated samples of the extruded materials were mounted on the sample holder using silver paint and uncoated samples of pure ABZ and physical mixtures ABZ – PVP K12 were mounted using double-sided conductive tape. Measurements were performed using a Hitachi SU 6600 high-resolution analytical FE-SEM (New York, United States) at 5.00 and 20.00 kV and a Zeiss IS50 (Oberkochen, Germany) at 20.00 kV.

2.5. Computed Tomography (μ-CT)

Cross-sections of the extruded materials were analysed by CT x-rays scanning to assess the internal void content (porosity) at a microstructural level, as well as sample uniformity by the

characterisation of the average molecular densities. A Bruker high resolution X-ray Micro-CT SkyScan 1272 (Kontich, Belgium) with an X-ray source voltage of 50 kV was used. The system was equipped with an aluminium 0.25 mm filter and 11 Mp CCD detector. Sample preparation required the introduction of a piece of extruded material inside a drinking straw to avoid any interference due to sample movement during measurement. Extruded material of ABZ – PVP K12 at 1/99 (% w/w) was analysed using a rotation step of 0.6° and extruded materials at 5/95 and 10/90 (% w/w) a rotation step of 0.10° and exposure time of 300 ms. The scanned images were reconstructed using the NRecon software (version 1.6.9.18, Bruker Micro-CT, Kontich, Belgium). To visualise and analyse the data, CTAn software (version 1.14.4.1, Bruker, Micro-CT, Kontich, Belgium) and CTVol software (version 2.2.3.0, Bruker Micro-CT, Kontich, Belgium) for surface rendering were used. A set of calculations within CTAn including image thresholding were applied to determine a region of interest (ROI) within the cross section of the extruded material and avoid any interference caused by the straw. Porosity calculations were performed considering the volume of internal closed pores which are completely surrounded by solid material.

2.6. X-Ray Powder Diffraction (XRPD)

All extruded materials were analysed by XRPD in order to determine the molecular transformation of the drug from crystalline to amorphous state. A Bruker AXS D8 advanced transmission diffractometer (Karlsruhe, Germany) with theta-theta geometry, primary monochromatic radiation (Cu Kα1λ = 1.54056 Å), a Braun 1D position sensitive detector (PSD) and an automated multi-position x-y sample stage were used. Raw materials and physical mixtures drug-polymer were also characterised, and their XRPD patterns compared with the extruded materials.

2.7. Differential Scanning Calorimetry (DSC)

Thermal analysis of the extruded materials, physical mixtures drug-polymer and raw materials was performed using a Mettler Toledo DSC 822^e (Greifensee, Switzerland) differential scanning calorimeter. A standard In/Zn calibration was performed and an inert gas such as N_2 was used to purge throughout the equipment at 150 mL/min. Samples were ground using a mortar and pestle then introduced into 40 µl sealed aluminium crucibles with a pierced lid. All samples were heated from 25 to 250 °C, melting temperature (Tm) of ABZ (208-210 °C), at a heating rate of 10 °C/min, data was evaluated using the Star® Evaluation Software and the Tg events were characterised using the inflection method.

2.8. Karl-Fischer studies for stability evaluation

A Mettler Toledo DL-39 Karl-Fischer instrument (Schwerzenbach, Switzerland) was used to assess the water content of the extruded materials after 1, 3 and 6 months storage. Previous sample preparation required grinding of the sample using a mortar and a pestle followed by dissolution of 10 mg of extruded material in 1 mL of methanol. Experiments were performed in chambers with controlled temperature and RH.

2.9. Dissolution profile studies

Dissolution studies of the extruded materials and physical mixtures were carried out using a Sirius T3 measurement system (East Sussex, United Kingdom). Sample preparation required manual grinding using a mortar and a pestle to a fine powder. Particle size distributions of these materials were analysed (sample measurement time of 3 s) using a Malvern Mastersizer 3000 (Worcestershire, United Kingdom) fitted with the *Aero S* dry dispersion unit, a micro tray and air pressure adjusted to 1 bar. Mean values (d_{10}, d_{50}, d_{90}) obtained for PM of ABZ – PVP K12 at 1/99, 5/95 and 10/90 % w/w were 21.11, 61.09, 110.38 µm, 15.41, 50.48, 97.78 µm and 10.55, 46.11, 90.46 µm, respectively. Moreover, mean values (d_{10}, d_{50}, d_{90}) of extruded materials at 1/99, 5/95 and 10/90 % w/w were 33.93, 197.46, 463.48 µm, 18.01, 123.54, 425.15 µm and 8.65, 88.90, 459.85 µm, respectively. Later sample preparation

included the formation of a 3 mm diameter single tablet by weighing between 7 to 12 mg of grinded material that was later considered for dosage adjustment of each formulation. Tablets were pressed using a custom made die and a Specac manual hydraulic press (Kent, United Kingdom) with a compaction pressure of 80 kN. A Sirius T3 measurement system was then used to obtain material dissolution profiles between pH values of 2 to 7. A stationary disk apparatus was used consisting of a tablet holder where die and tablet were inserted and analysed using 15 mL of acetate phosphate buffer dissolution media. The buffer media was used to simulate in-vitro gastrointestinal conditions by pH automatic adjustment from 2.0-3.7 (time 0-30min), 3.7-5.2 (time 30-60min), 5.2-7.1 (time 60-90min), and 7.1 (time 90-130min) and tablet surface facing the media to facilitate tablet erosion. Physical mixtures as well as extruded materials produced were analysed under non-sink conditions by a titration method. Datapoints were collected every 30 seconds by an spectroscopic UV dip-probe at a wavelength of 250 nm and transformed using pKa values (4.08; 10.34) and Molar Extinction Coefficient (MEC) into dissolution profile curves representing drug release (%) over time.

3. Results and discussion

3.1. Miscibility studies

The application of the *Hoy and Hoftzyer/Van Krevelen* method through the Hansen solubility parameter calculation evidenced that ABZ and PVP K12 are highly miscible, with a solubility parameter difference ($\Delta\delta$) of 5.70 $MPa^{1/2}$. Individual solubility parameter values (δ) for ABZ and PVP K12 were previously calculated based on the contribution of dispersive forces (E_d), polar interactions (E_p) and hydrogen bonds (E_h). Physical mixtures of ABZ and PVP K12 were also characterised by Hot-Stage Microscopy (HSM) to assess the miscibility properties of the two components and also their suitability for HME processing. Figure 1, a-d illustrates pure ABZ sample and images e-g the results of the physical mixture of ABZ – PVP K12 at 10/90 (% w/w) under different temperature conditions. Solid ABZ appears as dark crystals

using a 10x magnification lens, similar to the results observed by Moyano et al., (2014) using 100x magnification. In their study, commercial ABZ melting event is characterised at an onset temperature of 186 °C and complete melting is observed at 216 °C. Similar results are shown in Figure 1, images a to d where commercial ABZ particles are stable at temperatures between 45 to 180 °C but complete melting event is shown at 210 °C. A physical mixture, ABZ – PVP K12 at 10/90 (% w/w), shows a characteristic birefringence property that allows the differentiation between amorphous polymer and ABZ crystals (Fig. 1, e to g). Initial stages of polymer melting can be observed at a temperature of 145 °C (Fig. 1f) similar to DSC thermal analysis behaviour observed by Baird and Taylor (2012) and at 180 °C, drug crystals dissolve within the polymer indicating the miscibility properties of the two materials (Fig. 1g). These results confirm the ability of ABZ and PVP K12 to form a miscible system when temperatures above the Tg of the polymer are applied (Tg of PVP K12 = 90 °C) (Reintjes, 2011).

3.2. Scanning Electron Microscopy (SEM)

All formulations processed by HME were characterised by SEM microscopy in order to assess the physical state of the drug within the polymeric matrix, and extruded materials appear to be homogeneous when compared to the physical mixtures (Figure 2, b to d). It was also observed that as the amount of drug increased the porosity within the samples also increased which suggests that there is a correlation between the PVP K12 polymer and the proportion of drug in the system with the relaxation properties exhibited by the extruded materials (Sarode and Kumbharkhane, 2012). Moreover, polymer surface analysis of extruded materials (Figure 2, e to g) suggests the presence of a laminated surface characteristic of all samples.

3.3. Computed Tomography (μ-CT)

Extruded materials were scanned using a µ-CT instrument in order to show at a micro-molecular level the homogeneity properties and suitability of HME technique to obtain a high mixing degree product. Previous studies to assess drug content uniformity within HME systems incorporated a fluorescent dye (Park et al., 2013) however characterisation of materials internal structure by computed tomography (CT) has gained popularity as a useful tool to examine solid dosage forms such as tablets (Sinka et al., 2004) or granule intermediates (Crean et al., 2010) and more recently co-extruded materials (Vynckier et al., 2015). This technique offers the possibility to analyse the material's internal structure through X-rays scans and visualise density and porosity characteristics. Extruded materials comprising ABZ – PVP K12 at 1/99, 5/95 and 10/90 (% w/w) were analysed by µ-CT (Fig. 3, a-c) and the cross-section visualised by density characterisation shows an increase in porosity as well as different density levels from low (red) to medium (green) and high (blue) density values that correspond to the densities of air, polymeric material such as PVP K12 and ABZ. The porosity as shown in Figure 3 could be explained by entrapped air or by electrostatic interactions that occurred between ABZ and PVP K12. Moreover, 3D analysis and differences in the morphometric parameters obtained for all extruded materials can be observed in Table 2. It is then evidenced that the degree of porosity is influenced by the drug content within the extruded material and this is the first report of non-homogeneity in extruded materials at a micro-structural level. This is similar to reported micro-structure variations for tablets (Sinka et al., 2004), granules (Crean et al., 2010) and calendered tablets (Vynckier et al., 2015) where it was observed the influence of pores formed during co-extrusion into tablet adhesion degree between core and coat. Such studies indicate that despite the known mixing ability of twin-screw processing (Crowley et al., 2007) standard techniques for assessing homogeneity may not be adequate.

3.4. X-Ray Powder Diffraction (XRPD)

The XRPD patterns of ABZ – PVP K12 extruded formulations, drug-polymer physical mixtures (PM) and pure drug was analysed in order to investigate if any re-crystallisation events registered over time (Figure 4). The XRPD pattern of ABZ shows intensity peaks at 2θ angles of 6.91, 11.32, 13.83, 17.97, 19.51, 19.99, 20.75, 22.19, 23.85, 24.47, 24.72, 25.05, 26.08, 26.23, 27.21, 28.73, 29.06, 30.00, 30.52 and 31.05° that correspond to ABZ crystalline form I (Pranzo et al., 2010). However, the intensity of the peak observed at 25° 2θ is lower compared to the one observed by Pranzo et al., (2010). This may be due to specimen preparation errors in the commercial ABZ pattern reported by Pranzo et al., such as crystals non-random preferred orientation (Jenkins and Snyder, 1996).

The XRPD patterns of the physical drug-polymer mixtures (PM) and the extruded materials suggest the absence of a crystalline ordered structure of ABZ and the formation of an amorphous solid dispersion of the drug within the extruded polymer matrix. It can also be observed that by increasing ABZ content in the physical mixture (PM) samples, the height of the intensity peaks registered also increased (Fig. 4a). In contrast, the extruded materials do not show any intensity peaks relative to crystalline structures but a halo pattern characteristic of amorphous materials. By looking to the XRPD patterns obtained after 6 months storage of the extruded materials containing ABZ – PVP K12 at 10/90 (% w/w) (Fig. 4b), we can conclude that the materials are stable and there are no re-crystallisation events registered over time. Therefore, these results suggest that stable amorphous solid dispersions of ABZ in PVP K12 for all formulations were achieved.

3.5. Differential Scanning Calorimetry (DSC)

DSC analysis of the extruded materials, physical mixtures (PM) and raw materials was carried out to determine the formation of amorphous solid dispersions and also evaluate the presence of glass transition (Tg) events (Fig. 5). Differences between the Tg values of the extruded ABZ formulations and physical mixtures (PM) drug-polymer (differences in scale to

be considered) indicated that a solid form transformation of the ABZ crystals occurred during HME and the extruded material thermograms do not show evidence of any endothermic event due to melting of crystalline material. Also, differences regarding Tg appearance is observed and is normally considered a middle value comprised by the Tg values of the raw materials involved (Maru et al., 2011; Baird and Taylor, 2012). Figure 6 shows the DSC thermograms of all extruded materials after 6 months storage. The presence of two Tg events for the 1/99% (w/w) at 25 °C, 5/95% (w/w) at 25 °C, 10/90% (w/w) at 50 °C curves suggests that the material could have evolved to a solid glassy suspension. However, there is no evidence of recrystallisation events, conclude that extruded materials are stable over time. Moreover, the 1/99% (w/w) at 50 °C and 5/95% (w/w) at 50 °C appear to have one Tg event (solid dispersion), and the 10/90% (w/w) at 25 °C shows an amorphous curve without any Tg events due to the heating rate.

3.6. Karl-Fischer studies for stability evaluation

All the raw materials and extruded samples were analysed by Karl-Fischer titration to determine the water content, since the well-known hygroscopicity of some pharmaceutical grade polymers such as polyvinylpyrrolidone (PVP) can be a limitation due to its influence on the stability of amorphous solid dispersions (Bianco et al., 2013). Low water content values of dosage forms containing hygroscopic polymeric materials such as PVP constitute a crucial parameter to be evaluated as there is evidence indicating that intramolecular bonds of polymeric materials and therefore the polymer free volume and other properties like plasticity or elasticity can be affected by increases in water content (Szakonyi and Zelko, 2012). The water content within the samples is a quality attribute to ensure product stability and to preserve the product from degradation phenomena, often known as drug-polymer phase separation events (Rumondor and Taylor, 2009). Table 3 presents the water content (%) of the raw materials and the ABZ – PVP K12 formulation at 10/90 (% w/w) observed at zero

and 6 months after storage. As depicted in Table 3, stored samples did not show water content increase higher than 0.2 % despite the high hygroscopicity properties of PVP. Non-parametric ANOVA (Kruskal-Wallis) test was also performed indicating that temperature changes do not have a significant influence in samples water content ($P=0.288$ therefore $P>0.05$). Low water content values of 0.2 % are considered optimum for oral dosage forms in order to be stable and preserve their physicochemical properties. Solid dosage forms with water content values below 2 % are considered acceptable for a commercial pharmaceutical product although these values may differ depending on the type of product and specifications required.

3.7. Dissolution profile studies

Drug release of the extruded materials was characterised using a Sirius T3 measurement system under non-sink conditions and simulating gastrointestinal (GI) pH conditions. As can be observed in Figure 7, extruded materials (ABZ – PVP K12 ratios of 1/99 and 10/90 (% w/w)) increased release compared to the pure drug with values of 70 % drug release and extrapolated dissolution rates of 45.09 µg min^{-1} and 148.80 µg min^{-1}, respectively. Slightly lower values of 50 % drug release and extrapolated dissolution rate value of 171 µg min^{-1} were achieved by the extruded material containing 5/95 (% w/w). Similar results related to solid dispersions of a BCS Class II drug such as ABZ into a PVP matrix that showed such an increase in drug dissolution rate and a similar dissolution profile were observed by Frizon et al., (2013). Dissolution profiles of the extruded materials of ABZ – PVP K12 at 1/99 and 5/95 % (w/w) did not achieve supersaturation (ABZ solubility below 22.8 µg/ml). However, supersaturation of the system was achieved by ABZ – PVP K12 formulation at 10/90 % (w/w) with a solubility value of 30.33 µg/ml. It is of note in Figures 7 and 8 the increased and fast drug release profile (or also called “spring”) of the extruded materials that does not exhibit under the test conditions the characteristic “parachute” effect observed by Brouwers

et al., (2009). In our studies, an optimum drug release profile close to 100 % was not achieved and possible influence of the polymeric material PVP K12 needs to be further studied. Tablets did completely dissolved in the buffer media which suggests there is an effect of PVP that prevents the complete dissolution of ABZ leading to different proportions (%) of drug released over time, although this needs to be further studied. Moreover, dissolution studies of the extruded materials stored for 6 months at 25 °C and 50 °C revealed that the formulations were stable over time (Fig. 8). Extruded materials comprising 1/99 % (w/w) show a similar dissolution profile after 6 months storage in comparison to 5/95 % and 10/90% w/w which show variations of approximately 10% drug release. Similar improvements towards ABZ dissolution rate were achieved by Torrado et al., (1996) that manufactured successful amorphous solid dispersions of ABZ in PVP K12 by the classic solvent evaporation method and also carried out bioavailability studies in animals. We demonstrate the suitability of a lab scale HME process to obtain stable amorphous solid dispersions of ABZ with enhanced dissolution properties that could lead to novel formulations with enhanced oral bioavailability.

4. Conclusions

Amorphous solid dispersions of ABZ, an anthelmintic drug with poor water solubility properties, in PVP K12 matrix were produced by HME method. Evidence of solid form transformation of ABZ is proved by characterisation of the extruded materials using SEM, XRPD and DSC all of which indicate the formation of an amorphous drug polymer system. We also introduced a novel tool for the characterisation of HME materials, computed tomography (µ-CT), which provided an insight into internal material properties such as porosity and materials distribution indicating that despite the previous physicochemical results the strands are not homogeneous. The potential impact on pharmaceutical properties will have to be further investigated and maybe mitigated if the strands were pelletised or

milled before further processing. Analysis of the samples after 6 months storage did not indicate any drug re-crystallisation events, which suggest that the samples were stable over time. Main factors involved are the use of a polymeric material with high Tg such as PVP K12 as well as the possibility of a complex formation between the drug and the polymer that will be further studied. High dissolution rate increase of ABZ in gastrointestinal simulated media was achieved with values of 70 % drug release for the extruded materials containing ABZ – PVP K12 at 1/99 and 10/90 (% w/w). Six months storage under temperature controlled conditions did not affect the dissolution profiles and Karl-Fischer results showed that samples were not affected by water intake. To conclude, HME can be applied as a continuous manufacturing technique of novel oral dosage forms comprising ABZ without the need of further processing techniques in order to improve its dissolution behaviour and possible enhancement of oral bioavailability.

Acknowledgements

The authors would like to thank EPSRC and the Doctoral Training Centre in Continuous Manufacturing and Crystallisation for funding this work as well as the funding support and collaboration provided by the pharmaceutical companies AstraZeneca (Alderley Park, Cheshire, United Kingdom) and GlaxoSmithKline (Harlow, Essex, United Kingdom). The authors would also like to thank BASF (Cheshire, United Kingdom) for the kind donation of polymeric material.

References

Baird, J.A., Taylor, L.S., 2012. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Advanced drug delivery reviews 64, 396-421.

Bianco, S., Tewes, F., Tajber, L., Caron, V., Corrigan, O.I., Healy, A.M., 2013. Bulk, surface properties and water uptake mechanisms of salt/acid amorphous composite systems. International journal of pharmaceutics 456, 143-152.

Brouwers, J., Brewster, M.E., Augustijns, P., 2009. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. Journal of pharmaceutical sciences 98, 2549-2572.

Cheng, H., Friis, A., 2010. Modelling extrudate expansion in a twin-screw food extrusion cooking process through dimensional analysis methodology. Food and Bioproducts Processing 88, 188-194.

Crean, B., Parker, A., Roux, D.L., Perkins, M., Luk, S.Y., Banks, S.R., Melia, C.D., Roberts, C.J., 2010. Elucidation of the internal physical and chemical microstructure of pharmaceutical granules using X-ray micro-computed tomography, Raman microscopy and infrared spectroscopy. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 76, 498-506.

Crowley, M.M., Zhang, F., Repka, M.A., Thumma, S., Upadhye, S.B., Battu, S.K., McGinity, J.W., Martin, C., 2007. Pharmaceutical applications of hot-melt extrusion: part I. Drug development and industrial pharmacy 33, 909-926.

Eitzlmayr, A., Koscher, G., Reynolds, G., Huang, Z., Booth, J., Shering, P., Khinast, J., 2014. Mechanistic modeling of modular co-rotating twin-screw extruders. International journal of pharmaceutics 474, 157-176.

411 Forster, A., Hempenstall, J., Tucker, I., Rades, T., 2001. Selection of excipients for melt
412 extrusion with two poorly water-soluble drugs by solubility parameter calculation and
413 thermal analysis. International journal of pharmaceutics 226, 147-161.
414 Frizon, F., Eloy, J.d.O., Donaduzzi, C.M., Mitsui, M.L., Marchetti, J.M., 2013. Dissolution
415 rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent
416 methods. Powder Technology 235, 532-539.

417 Gue, E., Willart, J.F., Muschert, S., Danede, F., Delcourt, E., Descamps, M., Siepmann, J.,
418 2013. Accelerated ketoprofen release from polymeric matrices: importance of the
419 homogeneity/heterogeneity of excipient distribution. International journal of pharmaceutics
420 457, 298-307.
421 Jenkins, R., Snyder, R.L., 1996. Introduction to X-ray powder diffractometry. New York
422 Wiley.

423 Jones, D.S., Margetson, D.N., McAllister, M.S., Yu, T., Shu, L., McCoy, C.P., Andrews,
424 G.P., 2014. Thermodynamically stable amorphous drug dispersions in amorphous hydrophilic
425 polymers engineered by hot melt extrusion. Chemical Engineering Research and Design 92,
426 3046-3054.
427 Jung, H., Medina, L., García, L., Fuentes, I., Moreno-Esparza, R., 1998. Biopharmaceutics:
428 absorption studies of albendazole and some physicochemical properties of the drug and its
429 metabolite albendazole sulphoxide. Journal of pharmacy and pharmacology 50, 43-48.

430 Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for
431 poorly water-soluble drugs based on biopharmaceutics classification system: basic
432 approaches and practical applications. International journal of pharmaceutics 420, 1-10.

433 Kawakami, K., 2012. Modification of physicochemical characteristics of active
434 pharmaceutical ingredients and application of supersaturatable dosage forms for improving
435 bioavailability of poorly absorbed drugs. Advanced drug delivery reviews 64, 480-495.
436 Kelly, A.L., Halsey, S.A., Bottom, R.A., Korde, S., Gough, T., Paradkar, A., 2015. A novel
437 transflectance near infrared spectroscopy technique for monitoring hot melt extrusion.
438 International journal of pharmaceutics.

439 Lindenberg, M., Kopp, S., Dressman, J.B., 2004. Classification of orally administered drugs
440 on the World Health Organisation model list of essential medicines according to the
441 Biopharmaceutics Classification System. European journal of pharmaceutics and
442 biopharmaceutics 58, 265-278.
443 Madan, S., Madan, S., 2012. Hot melt extrusion and its pharmaceutical applications. Asian
444 Journal of Pharmaceutical Sciences 7(2), 123-133.
445 Maniruzzaman, M., Boateng, J.S., Bonnefille, M., Aranyos, A., Mitchell, J.C., Douroumis,
446 D., 2012. Taste masking of paracetamol by hot-melt extrusion: an in vitro and in vivo
447 evaluation. European journal of pharmaceutics and biopharmaceutics: official journal of
448 Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 80, 433-442.
449 Maniruzzaman, M., Morgan, D.J., Mendham, A.P., Pang, J., Snowden, M.J., Douroumis, D.,
450 2013. Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions.
451 International journal of pharmaceutics 443, 199-208.
452 Marriner, S.E., Morris, D.L., Dickson, B., Bogan, J.A., 1986. Pharmacokinetics of
453 Albendazole in man. European Journal of Clinical Pharmacology 30, 705-708.

454 Maru, S.M., de Matas, M., Kelly, A., Paradkar, A., 2011. Characterization of thermal and
455 rheological properties of zidovudine, lamivudine and plasticizer blends with ethyl cellulose to
456 assess their suitability for hot melt extrusion. European journal of pharmaceutical sciences:
457 official journal of the European Federation for Pharmaceutical Sciences 44, 471-478.

458 Maughan, L., Rhamzan, A., 2012. The evolution of QbD – From inception to maturity in
459 2012. Reg Rapporteur e.V 9, 9.
460 Michaeli, W., Frings, W., Höcker, H., Berghaus, U., 1993. Reactive Extrusion of Styrene
461 Polymers. International Polymer Processing 8, 308-318.

462 Moyano, J.R., Liró, J., Pérez, J.I., Arias, M.J., Sánchez-Soto, P.J., 2014. Thermal analysis of
463 Albendazole investigated by HSM, DSC and FTIR. Microscopy: advances in scientific
464 research and education (A. Méndez-Vilas, Ed.), 1043-1050.

465 Munos, B., 2009. Lessons from 60 years of pharmaceutical innovation. Nature reviews. Drug
466 discovery 8, 959-968.
467 Newman, A., Knipp, G., Zografi, G., 2012. Assessing the performance of amorphous solid
468 dispersions. Journal of pharmaceutical sciences 101, 1355-1377.
469 Park, J.B., Kang, C.Y., Kang, W.S., Choi, H.G., Han, H.K., Lee, B.J., 2013. New
470 investigation of distribution imaging and content uniformity of very low dose drugs using
471 hot-melt extrusion method. International journal of pharmaceutics 458, 245-253.
472 Pranzo, M.B., Cruickshank, D., Coruzzi, M., Caira, M.R., Bettini, R., 2010. Enantiotropically
473 related albendazole polymorphs. Journal of pharmaceutical sciences 99, 3731-3742.

474 Reintjes, T., 2011. Solubility enhancement with BASF pharma polymers. Solubilizer
475 Compendium.
476 Repka, M.A., Battu, S.K., Upadhye, S.B., Thumma, S., Crowley, M.M., Zhang, F., Martin,
477 C., McGinity, J.W., 2007. Pharmaceutical applications of hot-melt extrusion: Part II. Drug
478 development and industrial pharmacy 33, 1043-1057.

479 Rumondor, A.C.F., Taylor, L.S., 2009. Effect of Polymer Hygroscopicity on the Phase
480 Behavior of Amorphous Solid Dispersions in the Presence of Moisture. Molecular
481 Pharmaceutics 7, 477-490.

Sarode, A.V., Kumbharkhane, A.C., 2012. Dielectric relaxation and thermodynamic properties of polyvinylpyrrolidone using time domain reflectometry. Polymer International 61, 609-615.

Schilling, S.U., McGinity, J.W., 2010. Novel application of hot-melt extrusion for the preparation of monolithic matrices containing enteric-coated particles. International journal of pharmaceutics 400, 24-31.

Sinka, I.C., Burch, S.F., Tweed, J.H., Cunningham, J.C., 2004. Measurement of density variations in tablets using X-ray computed tomography. International journal of pharmaceutics 271, 215-224.

Stegemann, S., Leveiller, F., Franchi, D., De Jong, H., Lindén, H., 2007. When poor solubility becomes an issue: From early stage to proof of concept. European journal of pharmaceutical sciences 31, 249-261.

Szakonyi, G., Zelko, R., 2012. The effect of water on the solid state characteristics of pharmaceutical excipients: Molecular mechanisms, measurement techniques, and quality aspects of final dosage form. International journal of pharmaceutical investigation 2, 18-25.

Thiry, J., Krier, F., Evrard, B., 2015. A review of pharmaceutical extrusion: Critical process parameters and scaling-up. International journal of pharmaceutics 479, 227-240.

Torrado, S., Torrado S., Torrado, J.J., Cadórniga, R., 1996. Preparation, dissolution and characterization of albendazole solid dispersions. International journal of pharmaceutics 140, 247-250.

Van Zuilichem, D.J., Kuiper, E., Stolp, W., Jager, T., 1999. Mixing effects of constituting elements of mixing screws in single and twin screw extruders. Powder Technology 106, 147-159.

505 Verhoeven, E., Siepmann, F., De Beer, T.R., Van Loo, D., Van den Mooter, G., Remon, J.P.,
506 Siepmann, J., Vervaet, C., 2009b. Modeling drug release from hot-melt extruded mini-
507 matrices with constant and non-constant diffusivities. European journal of pharmaceutics and
508 biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische
509 Verfahrenstechnik e.V 73, 292-301.
510 Vynckier, A.K., Lin, H., Zeitler, J.A., Willart, J.F., Bongaers, E., Voorspoels, J., Remon, J.P.,
511 Vervaet, C., 2015. Calendering as a direct shaping tool for the continuous production of
512 fixed-dose combination products via co-extrusion. European Journal of Pharmaceutics and
513 Biopharmaceutics.

514 Zhang, G.G., Law, D., Schmitt, E.A., Qiu, Y., 2004. Phase transformation considerations
515 during process development and manufacture of solid oral dosage forms. Advanced drug
516 delivery reviews 56, 371-390.

517

518

519 **Figure captions**

520 Figure 1: Hot-stage microscopy (HSM, 10x magnification) images a to d: pure ABZ at 80 °C,
521 145 °C, 180 °C and 210 °C, images e to g: physical mixture (PM) ABZ – PVP K12 at 10/90
522 (% w/w) at 80 °C, 145 °C and 180 °C.

523 Figure 2: SEM images of pure drug (a), physical mixtures ABZ – PVP K12 at 1/99, 5/95 and
524 10/90 (% w/w) (b to d) and extruded materials of ABZ – PVP K12 formulation at 1/99, 5/95
525 and 10/90 (% w/w) (e to g).

526 Figure 3: Micro-CT single scanned images of extruded materials of ABZ – PVP K12 at 1/99,
527 5/95 and 10/90 % (w/w) (a, b and c).

528 Figure 4: Diffractograms of (a) ABZ – PVP K12 formulations at time zero and (b) ABZ –
529 PVP K12 at a 10/90 (% w/w) ratio after 6 months storage.

530 Figure 5: DSC thermograms of a: pure ABZ, b to d: physical mixtures (PM) of ABZ – PVP
531 K12 at 1/99 (% w/w), 5/95 (% w/w) and 10/90 (% w/w) and e to g: extruded materials of
532 ABZ – PVP K12 at 1/99 (% w/w), 5/95 (% w/w) and 10/90 (% w/w).

533 Figure 6: DSC thermograms after 6 months storage where a: extruded material of ABZ –
534 PVP K12 at 1/99 % (w/w) at 25 °C, b: extruded material of ABZ – PVP K12 at 1/99 % (w/w)
535 at 50 °C, c: extruded material of ABZ – PVP K12 at 5/95 % (w/w) at 25 °C, d: extruded
536 material of ABZ – PVP K12 at 5/95 % (w/w) at 50 °C, e: extruded material of ABZ – PVP
537 K12 at 10/90 % (w/w) at 25 °C and f: extruded material of ABZ – PVP K12 at 10/90 %
538 (w/w) at 50 °C.

539 Figure 7: Dissolution profiles simulating gastrointestinal conditions of a: pure ABZ, b to d:
540 physical mixtures (PM) of ABZ – PVP K12 at 10/90 (% w/w), 5/95 (% w/w) and 1/99 (%

w/w) and e to g: extruded materials of ABZ – PVP K12 at 5/95 (% w/w), 1/99 (% w/w) and 10/90 (% w/w). Standard error bars are based on 2 tests per sample.

Figure 8: Dissolution profiles simulating gastrointestinal conditions, upper left image (extruded material of ABZ – PVP K12 at 1/99% (w/w)): a: pure ABZ, b: extrudate at time zero, c: extrudate after 6 months storage at 50 °C, d: extrudate after 6 months storage at 25 °C; Upper right image (extruded material of ABZ – PVP K12 at 5/95 % (w/w)): a: pure ABZ, b: extrudate after 6 months storage at 25 °C, c: extrudate after 6 months storage at 50 °C, d: extrudate at time zero; Lower image (extruded material of ABZ – PVP K12 at 10/90 % (w/w)): a: pure ABZ, b: extrudate after 6 months storage at 25 °C, c: extrudate at time zero, d: extrudate after 6 months storage at 50 °C**.**

Table 1. HME processing parameters of ABZ – PVP K12 formulations

HME formulation	Barrel Zones	Barrel temperatures (°C, zones 1, 2, 3 and 4-8)	Screw speed (rpm)	Torque (Nm)	Throughput (Kg/h)
F1	1 - 8	70, 120, 140, 145	100	1.2 - 3	0.1 - 0.15
F2	1 - 8	70, 120, 140, 145	100	1.2 - 3	0.15
F3	1 - 8	70, 120, 140, 145	100	1.2 - 2.7	0.1 - 0.15

Description:

Table 1 shows the HME processing parameters applied for the development of three formulations comprising Albendazole (ABZ) and PVP K12 such as barrel temperatures and screw speed. Further information such as the torque values registered and the total throughput are also given.

552

553 Table 2. Morphometric parameters of extruded materials obtained by µ-CT 3D analysis

HME formulation	Object volume (mm^3)	Volume closed pores (mm^3)	Closed porosity (%)
F1	25.17	0.01	0.04
F2	26.17	0.65	2.43
F3	12.70	0.20	1.57

554

Description:

555 Table 2 above shows the µ-CT 3D analysis of the extruded materials such as the object
556 volume, defined as the total volume analysed based on the external dimensions of the strand
557 (diameter approximately 2.0 mm) and the closed pores, defined as the space within the object
558 volume, which is completely surrounded by solid material.

559

Table 3. Karl-Fischer results after storage

Materials	Storage conditions	Average water content (% w/w)
Extruded material ABZ – PVP K12 10/90 (% w/w) ratio	Time zero, room temperature	0.1591 ± 0.0084
	6 months at 25 °C, 20% RH	0.1445 ± 0.0387
	6 months at 50 °C, 3% RH	0.1796 ± 0.0037

Description:

Table 3 above shows the average water content values (% w/w) obtained by Karl-Fischer coulometric titration using methanol as dissolution media. Mean standard deviation (SD) values of 3 replicates calculated for each sample are depicted using ± symbol (Kruskal-Wallis test, P=0.288 therefore P>0.05).